Subjecting clinical laboratory-developed tests (LDTs) to FDA premarket medical device clearance threatens to freeze diagnostic innovation and replicate the catastrophic testing delays of early COVID-19, replacing agile clinical pathology iteration with bureaucratic gatekeeping. marginalrevolution.com